Treatment Outcome of Locally Advanced Non-small Cell Lung Cancer

국소적으로 진행된 비소세포폐암의 치료성적

  • Lee, Heui-Kwan (Department of Radiation Oncology, Chonbuk National University Hospital) ;
  • Lee, Sun-Young (Department of Radiation Oncology, Chonbuk National University Hospital) ;
  • Kim, Jung-Soo (Department of Radiation Oncology, Chonbuk National University Hospital) ;
  • Kwon, Hyoung-Cheol (Department of Radiation Oncology, Chonbuk National University Hospital)
  • 이희관 (전북대학교병원 방사선종양학과) ;
  • 이선영 (전북대학교병원 방사선종양학과) ;
  • 김정수 (전북대학교병원 방사선종양학과) ;
  • 권형철 (전북대학교병원 방사선종양학과)
  • Published : 2006.12.31

Abstract

$\underline{Purpose}$: We evaluated retrospectively the outcome of locally advanced non-small cell lung cancer patients treated with definitive radiotherapy to find out prognostic factros affecting survival. $\underline{Materials\;and\;Methods}$: 216 cases of stage IIIB non-small cell lung cancer were with treated radiotherapy at our Hospital between 1991 to 2002 and reviewed retrospectively. Cases were classified by mode of treatment and response to treatment. Patients showing complete response or partial response to treatment were included in the "response group", while those showing stable or progressive cancer were included in the "non-response group". $\underline{Results}$: 30 patients completed the planned radiotherapy treatments and 39 patients completed combined treatments or chemoradiotherapy. Median survival was 4.6 months for patients treated with radiotherapy and 9.9 months for those undergoing combined radiotherapy and chemotherapy. Survival rates for the first year were 13.3% with radiotherapy and 35.9% with chemoradiotherapy. In the second year, 3.3% of the radiotherapy patients survived and 20.5% of the patients receiving chemoradiotherapy survived. By the third year, 15.4% of the patients receiving the combined treatments survived. None of the patients treated with radiotherapy alone lived to the third year, however. Overall survival was significantly different between the radiotherapy patients and the combined chemoradiotherapy patients (p<0.001). In the response group, median survival was 7.2 months with radiotherapy and 16.5 months with combined therapy. In the non-response group, median survival was 4.4 months with radiotherapy and 6.7 months with combined treatments. Severe acute complications (grade 3) occurred in 2 cases using radiotherapy, and in 7 cases using combined therapy. $\underline{Conclusion}$: When the patients with stage IIIB non-small cell lung cancer received chemoradiotherapy, treatment response rate and overall survival was greater than with radiation alone.

목 적: 국소적으로 진행된 비소세포성 폐암에서 예후영향인자를 찾기 위하여 근치적 방사선 치료에 대한 성적을 후향적으로 평가하였다. 대상 및 방법: $1991{\sim}2002$년에 걸쳐 본원에서 방사선치료를 받은 stage IIIB 비소세포성 폐암 환자 216명의 의무기록을 후향적으로 분석하였다. 완전관해와 부분관해를 반응군(response group), 불변 및 진행성질환을 무반응군(non-response group)으로 묶어 분류하였다. 결 과: 근치목적의 방사선치료를 시행한 총 140명의 환자 중 방사선단독치료를 받은 환자는 68명, 항암화학제와 병용요법을 시행한 환자는 72명이었다. 계획된 방사선치료가 완료된 것은 단독에서는 30예, 병용요법에서는 39예였다. 중앙생존기간은 방사선 단독치료군에서는 4.6개월, 병용요법군에서는 9.9개월이었다. 1년, 2년 및 3년 생존율이 방사선 단독치료군에서는 13.3%, 3.3%, 0%였으며, 항암화학제 병용요법군에서는 각각 35.9%, 20.5%, 15.4%였다(p<0.001). 반응군에서 방사선 단독으로 치료한 환자는 중앙생존기간 7.2개월, 항암화학제 병용치료환자는 16.5개월이었고, 무반응군에서 단독치료 환자는 4.4개월, 병용치료환자는 6.7개월이었다(p=0.001). 치료반응과 항암화학요법의 병용이 전체생존율에 영향을 주었다(p<0.001). Grade 3 이상의 심한 합병증은 방사선 단독요법에서 2예(6.7%), 항암화학 병용요법에서 7예(17.9%)였다. 결 론: Stage IIIB 비소세포성 폐암에서 방사선치료와 더불어 항암화학치료를 병용했을 때, 방사선단독요법에 비해 치료반응률과 생존율이 더 높았다.

Keywords

References

  1. The World Health Organization (WHO). The World Health Report; 2003
  2. Ministry of Health and Welfare. 2002 Annual Report of the Korea Central Cancer Registry (Published in 2003)
  3. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423 https://doi.org/10.1093/jnci/83.6.417
  4. Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the pattern of failure in patients with unresectable non- oat cell carcinoma of the lung treated with definitive radiotherapy: report by the Radiation Therapy Oncology Group. Cancer 1987;59:1874-1881 https://doi.org/10.1002/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z
  5. Perez CA, Stanly K, Rubin P, Kramer S, Brady LW, Marks JE. Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 1980;6:987-994 https://doi.org/10.1016/0360-3016(80)90106-6
  6. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990;323:940-945 https://doi.org/10.1056/NEJM199010043231403
  7. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta- analysis. Ann Intern Med 1996;125:723-729 https://doi.org/10.7326/0003-4819-125-9-199611010-00003
  8. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995;76:593-601 https://doi.org/10.1002/1097-0142(19950815)76:4<593::AID-CNCR2820760409>3.0.CO;2-N
  9. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979
  10. Miller AB, Hogestraeten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214 https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
  11. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000;117:358-364 https://doi.org/10.1378/chest.117.2.358
  12. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524- 530 https://doi.org/10.1056/NEJM199202203260805
  13. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-2699 https://doi.org/10.1200/JCO.1999.17.9.2692
  14. Curran WJ, Scott C, Langer R, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003;22:2499
  15. Chang SH, Lee KJ, Lee SN. The results of definitive radiation therapy and the analysis of prognostic factors for non-small cell lung cancer. J Korean Soc Ther Radiol Oncol 1998;16: 409-423
  16. Ahn SJ, Chung WK, Nah BS, Nam TK, Kim YC, Park KO. Outcomes after radiotherapy in inoperable patients with squamous cell lung cancer. J Korean Soc Ther Radiol Oncol 2001;19:216-223